ALK and non-small cell lung carcinoma: ALK-targeted therapies that inhibit the ALK tyrosine kinase have been approved for use in NSCLC, including the approved ALK tyrosine kinase inhibitor (TKI) alectinib, which is the current recommended first-line ALK TKI in Japan [4–6].